Vistagen has reported another setback for its lead anxiety treatment fasedienol, after the investigational nasal spray failed to meet the primary and secondary endpoints in its second consecutive Phase 3 study for social anxiety disorder (SAD). Despite the disappointing outcome, the company believes post hoc analyses of patients with the most severe disease could provide a potential path toward regulatory discussions and future development.
- Vistagen’s Phase 3 PALISADE-4 trial failed to meet its primary endpoint in social anxiety disorder.
- The study also missed all key secondary endpoints.
- A post hoc analysis suggested statistically significant benefits among patients with very severe social anxiety.
- The company plans to discuss the findings with the FDA to determine possible next steps.
- The results follow another unsuccessful Phase 3 trial announced in late 2025, increasing uncertainty around fasedienol’s regulatory pathway.
The PALISADE-4 study enrolled 238 adults with social anxiety disorder and evaluated whether a single intranasal dose of fasedienol administered approximately 20 minutes before a simulated public speaking challenge could reduce anxiety symptoms. The primary endpoint measured changes in anxiety using the Subjective Units of Distress Scale (SUDS), a widely used patient-reported measure of acute anxiety. According to Vistagen, fasedienol did not demonstrate a statistically significant improvement over placebo on either the primary endpoint or any of the study’s secondary endpoints.
The latest results closely mirror the outcome of the earlier PALISADE-3 Phase 3 trial announced in December 2025, which also failed because of an unexpectedly strong placebo response. Those findings contrasted sharply with the company’s earlier PALISADE-2 study, which successfully met both its primary endpoint and a key secondary endpoint, fueling hopes that fasedienol could become the first acute, as-needed treatment approved for social anxiety disorder.
Following the PALISADE-4 readout, Vistagen executives emphasized that additional analyses revealed encouraging findings in a subgroup of patients with very severe social anxiety disorder. According to the company, this subgroup represented slightly more than half of the trial population.
“Those results certainly were disappointing,” CEO Shawn Singh said during a conference call discussing the data.
“However, our multiple post hoc analyses of the data in patients with very severe social anxiety disorder, amounting to slightly over half of the patients randomized in the trial, demonstrate significant findings we believe are important from clinical and regulatory perspectives.”
The post hoc analysis included 123 patients with very severe social anxiety. Within that subgroup, Vistagen reported nominally significant reductions in anxiety symptoms compared with placebo. While patients receiving fasedienol experienced an average 12.8-point reduction in SUDS scores, placebo recipients showed only a 3.7-point decline, substantially smaller than the placebo response observed across the full study population. The company believes the lower placebo effect in this subgroup may better reflect the drug’s therapeutic activity.
Because these analyses were conducted after completion of the trial rather than being specified in advance, they are considered exploratory and generally do not carry the same regulatory weight as pre-specified primary endpoints. Nevertheless, Vistagen said it intends to discuss the findings with the U.S. Food and Drug Administration (FDA) to determine whether additional development or regulatory options remain available.
Fasedienol belongs to a novel class of investigational intranasal therapies known as pherines, which are designed to activate neural pathways through receptors in the nasal cavity without requiring significant absorption into the bloodstream or direct penetration of the brain. The proposed mechanism differs from conventional anti-anxiety medications such as benzodiazepines and selective serotonin reuptake inhibitors (SSRIs), which typically require systemic exposure and, in many cases, chronic dosing. Vistagen has positioned fasedienol as a potential fast-acting, as-needed treatment for anxiety triggered by specific social situations.
Despite the recent efficacy setbacks, the company has continued preparing for a potential regulatory submission should future evidence prove supportive. Earlier this month, Vistagen announced that its clinical development program had exceeded the International Council for Harmonisation (ICH) E1 recommendations for long-term safety exposure, with more than 1,500 participants having received fasedienol across completed and ongoing studies. The company noted that it has not yet aligned with the FDA on the specific safety exposure requirements needed for a future New Drug Application (NDA).
The disappointing Phase 3 outcome follows several strategic changes made by Vistagen over the past year. After the PALISADE-3 failure, the company reduced its workforce by approximately 20% to conserve cash while continuing development of fasedienol and the remainder of its pherine pipeline. Management has repeatedly stated that the program remains its highest priority.
Social anxiety disorder affects more than 30 million adults in the United States and is characterized by intense fear and anxiety during social or performance situations. Although several antidepressants and anti-anxiety medications are approved for chronic treatment, there are currently no FDA-approved therapies specifically indicated for acute, situational use immediately before anxiety-provoking events such as public speaking.
The latest trial results leave the future regulatory pathway for fasedienol uncertain. While the second consecutive Phase 3 failure presents a significant challenge, Vistagen believes the favorable findings observed in patients with the most severe disease may support further discussions with regulators regarding the next steps for the program. The company has not announced whether it plans to conduct additional Phase 3 studies, indicating that future development plans will depend in part on feedback received from the FDA.
Vistagen has announced that its second Phase 3 clinical trial evaluating its investigational treatment for social anxiety disorder did not achieve its primary efficacy endpoint. Despite the disappointing outcome, Vistagen believes the overall clinical data may still support future development and discussions with regulators regarding a potential path forward.
The results represent another challenge for the company, but Vistagen remains committed to advancing innovative therapies for patients living with anxiety disorders, an area that continues to have significant unmet medical needs.
Vistagen Reports Mixed Phase 3 Results
According to Vistagen, the latest Phase 3 study did not demonstrate a statistically significant improvement over placebo on the trial’s primary endpoint. Clinical studies involving psychiatric disorders often face high placebo response rates, making it difficult to show clear treatment benefits even when promising signals are observed.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
